Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
Add to watchlist
29.78+0.74 (+2.55%)
At close: 03:00PM CST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close29.04
Open29.50
Bid29.78 x 0
Ask29.79 x 0
Day's Range29.36 - 30.36
52 Week Range27.00 - 75.46
Volume76,123,100
Avg. Volume48,145,651
Market Cap189.967B
Beta (5Y Monthly)0.53
PE Ratio (TTM)44.51
EPS (TTM)0.67
Earnings DateAug 18, 2022 - Aug 22, 2022
Forward Dividend & Yield0.17 (0.57%)
Ex-Dividend DateJun 10, 2021
1y Target Est51.76
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 600276.SS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Bloomberg

      The Unsung Winners and Biggest Losers of China's Rocky Markets in 2021

      (Bloomberg) -- In a year that’s seen China’s “common prosperity” agenda roil global equity markets, the nation’s policies also created a greater divide between stock winners and losers at home.Most Read from BloombergWHO Downplays Threat of Covid-19 Variant Found in FranceU.S. Logs Record 1 Million Virus Cases With Data DelayOmicron Cases Are Hitting Highs, But New Data Put End in SightHong Kong Scraps Flights, Shuts Bars, Gyms on Omicron ThreatHong Kong Vaccine Surge Sees Majority Pick Sinovac

    • Benzinga

      BeyondSpring Inks Plinabulin Agreement In Greater China

      BeyondSpring Inc (NASDAQ: BYSI) and Jiangsu Hengrui Pharmaceuticals Co Ltd have entered into an exclusive commercialization and co-development agreement for plinabulin in Greater China. In combination with G-CSF, Plinabulin is currently under FDA Priority Review and the China National Medical Products Administration for the prevention of chemotherapy-induced neutropenia (CIN). Related Content: BeyondSpring Stock Is Up More than 300%: What You Need To Know? BeyondSpring's 58%-owned subsidiary, Wa

    Advertisement
    Advertisement